Glaukos Completes Patient Enrollment In Pivotal Phase Of U.S. IDE Clinical Trial For iStent SUPRA Post author:Sam Post published:February 15, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Never Say Never: Why Taking Out Bristol-Myers Squibb Could Boost Pfizer's Value by $5 Billion March 27, 2017 Viking Therapeutics Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update March 21, 2017 Why Teva's Stock Could Crash Another 50% November 7, 2017
Never Say Never: Why Taking Out Bristol-Myers Squibb Could Boost Pfizer's Value by $5 Billion March 27, 2017
Viking Therapeutics Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update March 21, 2017